Lipofib

Fenofibrate, the active ingredient in Lipofib, is a fibrate presented as a micronised oral tablet for oral use. It is employed to lower elevated triglyceride levels and improve lipid profiles in adults with dyslipidaemia, including mixed dyslipidaemia and primary hypercholesterolemia.

GNH USA supplies Lipofib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for patients in need. The company adheres to stringent regulatory standards and ensures consistent product availability across global markets.

Fenofibrate acts on lipid metabolism disorders, helping to normalize triglyceride and cholesterol levels.

Hypertriglyceridemia: reduces serum triglycerides and lowers risk of pancreatitis. Mixed dyslipidemia: lowers triglycerides, modestly raises HDL and reduces LDL. Primary hypercholesterolemia: improves overall lipid profile when used with statins.

Fenofibrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increase in ALT/AST. - Muscle aches: mild myalgia without weakness.

Serious or Rare Side Effects: - Severe liver injury: jaundice or hepatitis. - Rhabdomyolysis: muscle breakdown with dark urine and possible renal impairment. - Allergic reactions: rash, pruritus or angioedema.

Before prescribing Lipofib, clinicians should consider several safety aspects. - Renal function: assess before initiating therapy in patients with impaired kidney function. - Hepatic function: monitor liver enzymes regularly during treatment. - Drug interactions: avoid concomitant use with potent CYP2C8 inhibitors. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Fenofibrate can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Cyclosporine: may increase fenofibrate plasma levels, raising risk of toxicity. - Gemfibrozil: combined fibrate therapy can markedly increase risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Statins (especially simvastatin): increased risk of muscle toxicity; monitor CK levels. - Warfarin: fenofibrate may enhance anticoagulant effect; monitor INR. - Antidiabetic agents: may affect glycemic control; monitor blood glucose.